← All trials
NCT04561076
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 9, 2020
- Primary completion
- Sep 6, 2021
- Completion date
- Sep 18, 2021
- First posted
- Sep 23, 2020
- Last posted
- Sep 24, 2020
- Enrollment
- 24
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hengenix Biotech IncLead sponsor
- ParexelOverall official - principal investigator
- Government of ChinaCollaborator
- Sanyou BiopharmaceuticalsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.